-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SOPHiA GENETICS (NASDAQ:SOPH) Vs. Allena Pharmaceuticals (NASDAQ:ALNAQ) Head to Head Survey
SOPHiA GENETICS (NASDAQ:SOPH) Vs. Allena Pharmaceuticals (NASDAQ:ALNAQ) Head to Head Survey
SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
Valuation & Earnings
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
Get SOPHiA GENETICS alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $40.45 million | 4.06 | -$73.68 million | ($1.48) | -1.75 |
| Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Allena Pharmaceuticals has lower revenue, but higher earnings than SOPHiA GENETICS.
Volatility and Risk
SOPHiA GENETICS has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.Analyst Ratings
This is a summary of current recommendations and price targets for SOPHiA GENETICS and Allena Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 0 | 1 | 1 | 0 | 2.50 |
| Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
SOPHiA GENETICS currently has a consensus target price of $7.00, suggesting a potential upside of 170.27%. Given SOPHiA GENETICS's higher possible upside, research analysts clearly believe SOPHiA GENETICS is more favorable than Allena Pharmaceuticals.
Profitability
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -210.25% | -39.47% | -33.12% |
| Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Insider and Institutional Ownership
31.0% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.2% of Allena Pharmaceuticals shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
SOPHiA GENETICS beats Allena Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About SOPHiA GENETICS
(Get Rating)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
索菲亚基因(纳斯达克：SOPH-GET评级)和艾琳娜制药(纳斯达克：ALNAQ-GET评级)都是小盘医疗公司，但哪一家是优势投资？我们将根据这两家公司的盈利能力、风险、收益、分析师建议、估值、股息和机构所有权等方面的实力进行比较。
Valuation & Earnings
估值与收益
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
该表格比较了索菲亚基因公司和Allena制药公司的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $40.45 million | 4.06 | -$73.68 million | ($1.48) | -1.75 |
| Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 索菲亚遗传学 | 4,045万美元 | 4.06 | -7,368万元 | ($1.48) | -1.75 |
| Allena制药公司 | 不适用 | 不适用 | -4,866万元 | 不适用 | 不适用 |
Allena Pharmaceuticals has lower revenue, but higher earnings than SOPHiA GENETICS.
Allena制药公司的收入低于索菲亚遗传公司，但收益高于索菲亚遗传公司。
Volatility and Risk
波动性和风险
Analyst Ratings
分析师评级
This is a summary of current recommendations and price targets for SOPHiA GENETICS and Allena Pharmaceuticals, as reported by MarketBeat.
据MarketBeat报道，这是对索菲亚遗传学和Allena制药公司目前的建议和价格目标的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 0 | 1 | 1 | 0 | 2.50 |
| Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 索菲亚遗传学 | 0 | 1 | 1 | 0 | 2.50 |
| Allena制药公司 | 0 | 0 | 0 | 0 | 不适用 |
SOPHiA GENETICS currently has a consensus target price of $7.00, suggesting a potential upside of 170.27%. Given SOPHiA GENETICS's higher possible upside, research analysts clearly believe SOPHiA GENETICS is more favorable than Allena Pharmaceuticals.
索菲亚基因目前的共识目标价为7美元，暗示潜在上涨170.27%。考虑到索菲亚基因公司更有可能的上行空间，研究分析师显然认为索菲亚基因公司比阿莱纳制药公司更有利。
Profitability
盈利能力
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了索菲亚基因公司和Allena制药公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -210.25% | -39.47% | -33.12% |
| Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 索菲亚遗传学 | -210.25% | -39.47% | -33.12% |
| Allena制药公司 | 不适用 | -287.46% | -146.58% |
Insider and Institutional Ownership
内部人与机构持股
31.0% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.2% of Allena Pharmaceuticals shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
索菲亚基因公司31.0%的股份由机构投资者持有。相比之下，Allena制药公司0.2%的股份由机构投资者持有。Allena PharmPharmticals 3.7%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一只股票有望实现长期增长。
Summary
摘要
SOPHiA GENETICS beats Allena Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
索菲亚遗传在两只股票比较的10个因素中有6个击败了Allena PharmPharmticals。
About SOPHiA GENETICS
关于索菲亚遗传学
(Get Rating)
(获取评级)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
索菲亚基因公司是一家医疗保健技术公司。该公司提供索菲亚DDM平台，这是一个基于云的软件即服务平台，用于分析数据并从多模式数据集和诊断模式中生成见解。其索菲亚DDM平台和相关的解决方案、产品和服务被世界各地的医院、实验室和生物制药所使用。索菲亚遗传集团成立于2011年，总部设在瑞士圣苏尔皮斯。
About Allena Pharmaceuticals
关于Allena制药公司
(Get Rating)
(获取评级)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Allena制药公司是一家生物制药公司，在美国发现、开发和商业化口服酶疗法，用于治疗罕见和严重的代谢以及肾脏疾病患者。它的主要候选产品是ALLN-346，这是一种新型的尿酸降解酶，适用于晚期慢性肾脏疾病中的高尿酸血症和痛风患者。该公司成立于2011年，总部设在马萨诸塞州牛顿市。2022年9月2日，Allena制药公司根据破产法第11章向美国特拉华州地区破产法院提交了自愿重组请愿书。
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
接受《索菲亚遗传学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对索菲亚遗传学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧